Every dotMD research breakdown translates peer-reviewed human clinical trials from NEJM, The Lancet, JAMA, BMJ, and NCBI PubMed (6,255 indexed studies) into warm, plain English—complete with Absolute Risk Reduction (ARR), Number Needed to Treat (NNT), participant sample sizes (N), and direct links to the primary paper.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Every enzyme that converts Vitamin D3 into its active hormone form requires magnesium; pairing 200–300 mg elemental Magnesium Glycinate with Vitamin D3 normalizes 25(OH)D levels faster.
Evening Magnesium Bisglycinate (200–320 mg elemental) taken 60 minutes before bed shortens sleep onset, increases deep slow-wave sleep, and lowers nighttime cortisol without morning hangover.
Chelated Magnesium Bisglycinate absorbs via dipeptide amino-acid channels rather than passive mineral pores, delivering high cellular uptake without the osmotic laxative effect of Oxide or Citrate.
The study revealed that magnesium, potassium, and magnesium and potassium combined had a significant effect on serum cortisol and melatonin levels (sleep hormones).
The study suggested the addition of naldemedine as an effective treatment option for opioid-induced constipation in cancer patients insufficiently responding to magnesium oxide treatment.
Mg can serve as a protective agent against CIN, as it reduces renal injury biomarkers, including urinary KIM-1, urinary NGAL, serum sFasL, and serum MDA when incorporated into treatment regimens at different doses, compared to cisplatin alone.
High-dose magnesium appeared safe with only a modest possible benefit of medical readiness for discharge at 12 h.
Prehospital magnesium followed by alteplase was feasible and safe but did not demonstrate a significant overall clinical benefit.
Magnesium supplementation in women with PCOS had a significant positive effect on improving total quality of life.
The purpose of this study is to determine whether the addition of magnesium to bupivacaine for the post-operative adductor canal blocks (ACB) can decrease opioid consumption and improve pain management for patients after same-day discharge
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
